A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer

Clinical trial NCT06532006 · RECRUITING

Trial details

NCT number: NCT06532006
Sponsor: Shanghai Henlius Biotech
Status: RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Gastroesophageal-junction Cancer Monoclonal Antibody Gastric Cancer HER2-positive Gastric Cancer

Start date: 2024-11-22
Primary completion: 2027-06-01
Enrollment: 550

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.